MedTrace Logo

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

NCT03410979 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2018-01-25

No results posted yet for this study

Summary

This study is a first-in-human (FIH), Phase I, single center, randomized, double-blind, placebo-controlled, sequential group study in healthy male subjects to assess the safety, tolerability and PK of single ascending oral doses of GLPG2737 and multiple ascending oral doses of GLPG2737 administered for 14 days.

Conditions

  • Healthy

Interventions

DRUG

GLPG2737 single dose

GLPG2737 oral suspension, single ascending doses

DRUG

Placebo single dose

Placebo, oral suspension.

DRUG

GLPG2737 multiple dose

GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.

DRUG

GLPG2737 multiple dose

Placebo, oral suspension, daily for 14 days

Sponsors & Collaborators

  • Galapagos NV

    lead INDUSTRY

Principal Investigators

  • Chris Brearley, BM, MRCP, MFPM · Galapagos NV

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-25
Primary Completion
2017-08-15
Completion
2017-08-15

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03410979 on ClinicalTrials.gov